BRAF CODON 600 VARIANT TESTING IN MALIGNANT MELANOMAS TO PREDICT RESPONSE TO BRAF KINASE INHIBITORS Approximately 40 to 60% of cutaneous melanomas carry activating variants in BRAF that lead to the constitutive activation of downstream signaling through the MAPK pathway. Approximately 90% of these variants result in the substitution of glutamic acid for valine at codon […]
ViewEXCELLING IN SCIENCE & SERVICE